Clinical Trial

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.
Protocol Amendment History 2 changes
minor Trial arms changed: 1 -> 2 2026-07-19
critical Recruitment opened 2026-04-07
Trial Details
NCT Number NCT07505771
Lead Sponsor Immunome, Inc.
Conditions Solid Malignancies
Enrollment 105 participants
Start Date 2026-06-19
Primary Completion 2029-12 (estimated)
Study Completion 2034-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-29